1. Home
  2. CFFN vs SVRA Comparison

CFFN vs SVRA Comparison

Compare CFFN & SVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Capitol Federal Financial Inc.

CFFN

Capitol Federal Financial Inc.

HOLD

Current Price

$8.07

Market Cap

981.1M

Sector

Finance

ML Signal

HOLD

SVRA

Savara Inc.

HOLD

Current Price

$5.14

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CFFN
SVRA
Founded
1893
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Savings Institutions
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
981.1M
1.1B
IPO Year
2010
2009

Fundamental Metrics

Financial Performance
Metric
CFFN
SVRA
Price
$8.07
$5.14
Analyst Decision
Hold
Buy
Analyst Count
2
9
Target Price
$7.25
$7.33
AVG Volume (30 Days)
605.2K
1.5M
Earning Date
04-29-2026
05-13-2026
Dividend Yield
4.51%
N/A
EPS Growth
79.31
N/A
EPS
0.32
N/A
Revenue
$16,300,000.00
N/A
Revenue This Year
$20.16
N/A
Revenue Next Year
$6.62
$430.87
P/E Ratio
$25.22
N/A
Revenue Growth
6.54
N/A
52 Week Low
$5.71
$1.98
52 Week High
$8.13
$7.01

Technical Indicators

Market Signals
Indicator
CFFN
SVRA
Relative Strength Index (RSI) 62.82 48.82
Support Level $7.49 $5.10
Resistance Level N/A $5.43
Average True Range (ATR) 0.14 0.25
MACD 0.03 0.00
Stochastic Oscillator 88.99 55.00

Price Performance

Historical Comparison
CFFN
SVRA

About CFFN Capitol Federal Financial Inc.

Capitol Federal Financial Inc is a bank holding company that operates through its wholly-owned subsidiary bank. The bank is a community-oriented financial institution that offers a variety of financial services through tens of locations. It mainly serves metropolitan areas within the state of Kansas. The bank performs traditional banking functions such as deposit-taking activities and investing that money in first-lien residential mortgages. It also participates in commercial real estate loans with other lenders, investing those funds in various securities. The vast majority of the bank's loan portfolio is in originated one- to four-family real estate loans. Its primary source of income is net interest income.

About SVRA Savara Inc.

Savara Inc is a clinical-stage biopharmaceutical company. It is focused on rare respiratory diseases. It has one segment specialty pharmaceuticals within the respiratory system. The company's main product candidate, molgramostim, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP).

Share on Social Networks: